Home›Trial›NCT06947304
NCT06947304Phase 1RECRUITING

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Study Summary

A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Conditions
Nonalcoholic Steatohepatitis (NASH)Metabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions / Drugs
Miricorilant
View on ClinicalTrials.gov ↗
Sponsor
CORT
Corcept Therapeutics
Endocrinology
C53/100
Study Details
Enrollment8 participants
Primary Completion—
Lead SponsorCorcept Therapeutics
Data Retrieved2026-04-11 04:10:22.666705+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

Phase 1 trials primarily test safety and dosing in a small number of participants (typically 20–100). Results do not yet speak to efficacy. FDA approval is typically many years away from this stage.

Status & Expected Data

Currently recruiting: the trial is enrolling patients. A data readout is not expected until after enrollment closes and the follow-up period is complete.

Enrolled: 8 participants
Sponsor Catalyst Profile

Corcept Therapeutics (CORT) is the sponsoring company for this trial. BiotechSign currently grades this company C (53/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

CORT Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.